drugset
drugset / Trial / NCT01712308

Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia

NCT01712308 ↗

Phase 2 Completed 56 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This phase II trial studies the side effects of and how well sotatercept works in treating patients with myeloproliferative neoplasm-associated myelofibrosis or anemia. Sotatercept may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2013-02-21
Primary completion
2022-05-24
Completion
2022-05-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Sotatercept Protein / enzyme biologic — Subcutaneous
Background Ruxolitinib Small molecule — —

Indications

anemia myelodysplastic/myeloproliferative neoplasm myelofibrosis